Patents by Inventor Colin Gegg

Colin Gegg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antagonists of the bradykinin B1 receptor
    Publication number: 20050215470
    Abstract: The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.
    Type: Application
    Filed: October 21, 2004
    Publication date: September 29, 2005
    Inventors: Gordon Ng, Yue-Sheng Li, Colin Gegg, Benny Askew, Thomas Storz, Yuelie Lu, Derin D'Amico
  • Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
    Publication number: 20050124537
    Abstract: The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise: (a) a PTH/PTHrP modulating domain; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain or through a sidechain at any residue from residue 14 through the C-terminal residue. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is PEG. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein.
    Type: Application
    Filed: October 31, 2001
    Publication date: June 9, 2005
    Inventors: Paul Kostenuik, Colin Gegg, Mark Jarosinski, Olaf Kinstler
  • Chemically modified novel erythropoietin stimulating protein compositions and methods
    Publication number: 20030166566
    Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).
    Type: Application
    Filed: April 7, 2003
    Publication date: September 4, 2003
    Applicant: Amgen Inc.
    Inventors: Olaf Kinstler, Colin Gegg, Aimee Freeman, Thomas Boone
  • Chemically modified novel erythropoietin stimulating protein compositions and methods
    Patent number: 6586398
    Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: July 1, 2003
    Assignee: Amgen, Inc.
    Inventors: Olaf Kinstler, Colin Gegg, Aimee Freeman, Thomas Boone
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Publication number: 20030023048
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Application
    Filed: May 6, 2002
    Publication date: January 30, 2003
    Applicant: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Patent number: 6420340
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: July 16, 2002
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
    Patent number: 6420339
    Abstract: The present invention relates generally to the chemical modification of biologically active agents. More, specifically, the invention relates to a novel approach to engineer, through mutagenesis and site-directed chemical conjugation, specific, well-defined dualPEGylated-protein bioconjugates, consisting of two polyethylene glycol (PEG) macromolecules chemically conjugated to the protein at two specifically defined amino acid residues. The described dualPEGylated-protein bioconjugates show substantially improved bioefficacy and biocompatibility.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: July 16, 2002
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Publication number: 20010002419
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Application
    Filed: December 19, 2000
    Publication date: May 31, 2001
    Applicant: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Patent number: 6204247
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: March 20, 2001
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
    Patent number: 6017876
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: January 25, 2000
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Patent number: 5900404
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: May 4, 1999
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler